The Quebec advantage

Quebec is a world leader in early-stage clinical trials. Here’s why.

Reputation and quality

The world’s major pharmaceutical companies conduct over 5,000 clinical trials in Canada every year; 40% of these are carried out in Quebec.

Quebec is a preferred location for its medical and scientific expertise, state-of-the-art infrastructure and research-friendly economic and regulatory environment.

Renowned clinician-researchers

  • Our clinician-researchers are internationally recognized for their major medical discoveries and innovations in all therapeutic areas.
  • Leaders in personalized medicine and artificial intelligence.

State-of-the-art infrastructure

  • Our hospital and research centres rank among the best in the world.
  • Investments totalling 10 billion dollars in our hospital infrastructure guarantee high standards of quality and safety for carrying out early-stage clinical trials.

A public health system

  • A universal health care system that blends health care with research and teaching and facilitates patient recruitment and the conduct of all phases of clinical trials.
  • An ethnically diverse population facilitates clinical trials in all therapeutic areas.

An efficient regulatory approach

  • Health Canada ensures a 30-day regulatory review process.
  • Quebec provides a unified ethical review framework for studies conducted in more than one public institution.

Attractive financial incentives

  • Significant savings thanks to R&D incentives and a favourable Canadian exchange rate.
  • Reasonable labour costs for highly qualified employees.

Quebec, a preferred location for conducting early-stage clinical trials.

Find out more about CATALIS’ vision and mission.